http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020123852-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5f8c62a76b821cd339ad20215192d74 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate | 2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ff300b6f5648ad4e6733fa2b647e2b2 |
| publicationDate | 2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020123852-A1 |
| titleOfInvention | Method to prevent and treat ocular cataract by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers |
| abstract | A method is provided to prevent and to treat ocular cataract by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or angiotensin receptor blockers (ARB), and more particularly, to a method to prevent and treat ocular cataract by using calcium channel blockers, Angiotensin-Converting Enzyme Inhibitors, or angiotensin receptor blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where ocular cataract is formed, to increase the capillary network and augment the blood supply to the ocular lens. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023310380-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023310471-A1 |
| priorityDate | 2018-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1112.